Viatris Inc vs Energy Select Sector SPDR Fund — how do they compare? Viatris Inc trades at $17.64 (market cap $20.03B), while Energy Select Sector SPDR Fund trades at $65.13 (market cap $40.84B). The key difference: Energy Select Sector SPDR Fund is far larger — about 2× Viatris Inc's market cap, and Viatris Inc pays a 2.75% dividend while Energy Select Sector SPDR Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Viatris Inc for 57 Days and Energy Select Sector SPDR Fund for 67 Days on average.
| VTRS | XLE | |
|---|---|---|
Market Cap | $20.03B | $40.84B |
Volume | 14,109,977 | 50,409,268 |
Sector | Health | — |
52-Week High | $18.27 | $65.93 |
52-Week Low | $9.74 | $42.61 |
Typical Hold Time | 57 Days | 67 Days |
Enterprise Value | $32.15B | — |
Dividend Yield | 2.75% | — |
Signals from Pluang's Aura AI — not financial advice
Viatris (VTRS) trades at $17.64, up 0.86% on the day, with a bullish technical signal from moving averages and oversold RSI levels. The company has beaten earnings estimates for three consecutive quarters, with Q2 2026 EPS of $0.69 exceeding expectations. Revenue for 2025 was $14.3 billion, though net income was negative. Analyst consensus is a 'Buy' with a $22.17 price target, representing 26% upside. Recent news highlights include a new drug approval in Japan and recognition as a top employer.
The outlook for VTRS is cautiously optimistic, supported by earnings beats and a positive analyst stance, but tempered by negative profit margins and high debt. Key opportunities include operational cash flow strength and pipeline progress, while risks involve sustained profitability challenges and competitive pressures in the generics market.
XLE trades at $65.27, up 2.98% on the day, with a bullish technical signal from moving averages but caution from oscillators like the RSI at 70.16. The ETF, heavily concentrated in oil and gas, benefits from rising oil prices above $100 amid Middle East tensions and supply constraints. Recent news highlights strategic oil reserve releases and diesel price pressures, influencing energy sector volatility.
Outlook remains tied to oil price dynamics, with upside from sustained geopolitical risks but downside if crude reverses. Risks include oil market volatility and potential Fed rate hikes. Analyst sentiment is mixed, balancing energy sector strength against overbought technicals.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as energy companies by the GICS®, including securities of companies from the following industries: oil, gas and consumable fuels; and energy equipment and services. It is non-diversified.
Read more on XLE →